VIDEO: Finerenone provides significant reduction in time to dialysis
In this video, George L. Bakris, MD, a professor of medicine and the director of the American Heart Association-accredited Comprehensive Hypertension Center, University of Chicago Medicine, spoke about FIDELITY data released at ASN Kidney Week.
FIDELITY is the prespecified pooled analysis of the FIDELIO-DKD and FIGARO-DKD trials of patients with chronic kidney disease associated with type 2 diabetes.
Bakris and colleagues investigated the role of finerenone (Kerendia, Bayer) on renal outcomes by baseline therapy. In the study of more than 13,100 patients with more than 3 years of median follow-up, the researchers found finerenone reduced the risk of the kidney composite outcome by 23% compared with placebo. Additionally, researchers found a statistically significant 20% reduction in the time to dialysis, as well as consistent benefits across all subgroups. Overall safety was similar between the groups.
“If you use finerenone in people at high cardiovascular risk and/or those [who] have diabetes and kidney disease, you are going to get significant renal benefit, not just in slowing progression in terms of doubling of creatinine,” he said. “You are also going to get a benefit in terms of significant reduction in time to dialysis.”